PFE · 10-Q · 2026Q3 · Full report
ViiV Investment Exit
PFIZER INC · 2026-11-03 · Importance 48 · Surprise 42 · Matches filing data
Pfizer completed the sale of its 11.7% investment in ViiV on March 31, 2026, during its second fiscal quarter. The transaction generated $1.875 billion in cash proceeds. The sale contributed to a $1.870 billion net gain included in the first-nine-month 2026 non-GAAP reconciliation. The investing-cash-flow discussion also identifies $1.9 billion of proceeds from the ViiV investment sale.
Key facts
- On March 31, 2026, Pfizer completed the exit of its 11.7% investment in ViiV and received $1.875 billion in cash proceeds. source
- The change in Pfizer's investing activities was partly driven by $1.9 billion of proceeds from the sale of its ViiV investment in 2026. source
- Pfizer recorded a net gain in 2026 from the sale of its previous investment in ViiV, partially offsetting the first-nine-months unfavorable change in Other (income)/deductions—net. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | positive | realized | +0.9% | On March 31, 2026, Pfizer completed the exit of its 11.7% investment in ViiV and received $1.875 billion in cash proceeds. |